IGC Pharma, Inc.

IGC Healthcare Biotechnology

IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024. In the quarter to June 2026, revenue fell 19.7%, EPS fell 100.0%, free cash flow fell 103.3% and total debt rose 713.5%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

0.25 0.00 0.00%
Market cap
$26.3M
P/E
0.0×
Fwd P/E
−3.6×
Dividend yield
—
F-score
3/9
Altman Z
−16.58
Beneish M
−3.69
Dividend safety
n/a
Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24 Mar '25
Piotroski F-Score
— 4 2 4 1 3 3 2 3 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(2.81) (4.92) (3.82) 47.71 1.60 11.74 3.72 (5.32) (13.56) (16.58)
P/S ratio
1.34 20.78 6.88 13.97 4.75 83.65 119.63 19.62 21.00 17.55
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(6.50) (12.95) (13.71) 38.00 6.02 6.74 (3.07) (14.98) (40.19) (47.49)
Beneish M-Score
(3.29) 1.62 15.01 (2.02) (2.59) 0.28 (4.32) (2.80) (6.53) (3.69)
P/Operating CF
(54.03) (8.67) (7.81) (21.47) (2.23) (6.95) (6.36) (2.54) (5.43) (30.55)
P/B ratio
0.61 1.64 1.87 2.13 0.73 2.29 1.99 1.20 3.86 3.52
EV/Sales
1.26 21.42 6.32 8.99 1.85 68.00 93.65 16.25 20.31 17.44
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
(33.41) (5.79) (4.08) (8.18) (0.32) (2.76) (2.48) (1.18) (2.60) (4.23)
Current Ratio
1.20 2.78 1.37 30.44 9.12 9.93 6.19 3.41 1.58 1.28
Net Debt/EBITDA
0.22 (0.14) (0.24) 5.58 1.76 1.70 0.70 0.29 0.12 0.04
Debt/Equity
0.07 0.36 0.28 0.00 0.02 0.02 0.01 0.01 0.02 0.02
ROE
(19.57%) (17.53%) (23.17%) (19.68%) (24.34%) (29.70%) (52.97%) (59.30%) (116.95%) (104.33%)
ROA
(14.33%) (12.39%) (16.14%) (18.08%) (23.06%) (27.17%) (47.90%) (52.29%) (96.01%) (76.37%)
ROIC
(13.48%) (16.95%) (13.18%) (36.22%) (29.12%) (29.07%) (71.03%) (61.80%) (97.82%) (76.81%)
Return on Tangible Assets
(36.39%) (57.53%) (25.17%) (12.91%) (28.58%) (27.54%) (67.98%) (90.02%) (256.92%) (184.53%)
Average Days of Receivables
55.19 473.48 92.87 5.99 11.92 71.13 114.92 42.87 10.58 9.76
Earnings Yield
(32.69%) (14.89%) (12.96%) (6.93%) (36.73%) (12.29%) (32.63%) (64.71%) (45.83%) (30.36%)
Free Cash Flow Yield
(2.83%) (17.82%) (22.55%) (7.86%) (121.81%) (29.44%) (31.52%) (70.28%) (37.15%) (23.48%)
Free Cash Flow per Share
(0.02) (0.06) (0.08) (0.10) (0.33) (0.29) (0.16) (0.14) (0.10) (0.07)
Book value per Share
0.85 0.29 0.29 0.95 0.67 0.78 0.48 0.28 0.12 0.08
Free Cash Flow
(0.28) (1.54) (2.13) (3.39) (13.14) (12.34) (8.20) (7.13) (5.67) (5.24)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Oct 2026